Mycobacterium Infections clinical trials
The registry lists 59 studies for Mycobacterium Infections across more than 10 countries. 14 are recruiting or about to start. 10 of them are mainly about Mycobacterium Infections (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its 9 narrower conditions too, such as Tuberculosis: 1,721 studies, 299 open.
Get an email when these change. Save the Mycobacterium Infections studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
National Institute of Allergy and Infectious Diseases (NIAID) (9) · Centre Hospitalier Universitaire, Amiens (3) · Vanderbilt University (2) · National Jewish Health (2) · National Institutes of Health Clinical Center (CC) (2) · Otsuka Pharmaceutical Development & Commercialization, Inc. (2) · Manresana de Micobacteriologia, SL (2) · Bioniche Life Sciences Inc. (2)
What is being tested here
Drugs under test in Mycobacterium Infections studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 3, phase 3 first
- Sep 2027Shortened Regimen for Drug-susceptible TB in Children · Phase 3 · Johns Hopkins University
- Dec 2026Mycobacteriophage Treatment of Non-tuberculosis Mycobacteria · National Jewish Health
- Dec 2026Patients With Tuberculosis, Mycobacteriosis or Latent Tuberculosis · IRCCS Azienda Ospedaliero-Universitaria di Bologna
Who these studies take
Of the 12 Mycobacterium Infections studies recruiting now, 7 (58%) set no upper age limit and 1 (8%) stop at 75 or younger. 4 (33%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 3 (25%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 3 (25%) | 3 (25%) |
| 18 | 11 (92%) | 11 (92%) |
| 30 | 11 (92%) | 11 (92%) |
| 40 | 11 (92%) | 11 (92%) |
| 50 | 11 (92%) | 11 (92%) |
| 65 | 11 (92%) | 11 (92%) |
| 75 | 11 (92%) | 11 (92%) |
| 85 | 11 (92%) | 11 (92%) |
Across all 59 studies, recruiting or not: 25% stop at 75 or younger and 20% at 65; 34% take children; 0% are for women only and 2% for men only; 17% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 50 of 59. Browse all 59 → or search them.
- Study of Mycobacterial InfectionsRecruitingNCT000180441 country
- Shortened Regimen for Drug-susceptible TB in ChildrenRecruitingNCT06253715Phase 37 countries
- Training Protocol on the Natural History of TuberculosisRecruitingNCT012120031 country
- Amikacin Liposome Inhalation Suspension for Treatment of Mycobacterium Xenopi Pulmonary InfectionRecruitingNCT06585020Phase 21 country
- China Aortic Infection and Graft Infection Study: An Ambispective CohortRecruitingNCT078473461 country
- Transmission and Acquisition of Nontuberculous Mycobacteria Outbreak Investigation (TrANsMIt)RecruitingNCT061557471 country
- Emergency PWAS in Respiratory Infectious DiseaseRecruitingNCT053368511 country
- Mycobacteriophage Treatment of Non-tuberculosis MycobacteriaEnrolling by invitationNCT062622821 country
- Clinical Study on the Early Bactericidal Activity of Sitafloxacin Against Mycobacterium Abscessus DiseaseEnrolling by invitationNCT06809413Phase 21 country
- Patients With Tuberculosis, Mycobacteriosis or Latent TuberculosisRecruitingNCT067645761 country
- Gene Expression Profiles in Spinal Tuberculosis.RecruitingNCT056100981 country
- Mycobacteria Registry Study: Prospective Observational Study in AustriaRecruitingNCT065223471 country
- M. Avium WGS During Mav-PD TreatmentRecruitingNCT062664421 country
- Drug Exposure and Minimum Inhibitory Concentration in the Treatment of MAC Lung DiseaseRecruitingNCT058249881 country
- Comparing Expectorated and Induced Sputum and Pharyngeal Swabs for Cultures, AFB Smears, and Cytokines in Pulmonary Nontuberculous Mycobacterial InfectionCompletedNCT011507211 country
- Toxicity of Treatments for Non-tuberculous Mycobacterial Infections in Cancer Patients or NotCompletedNCT050307011 country
- Study of Epetraborole in Patients With Treatment-refractory MAC Lung DiseaseTerminatedNCT05327803Phase 2/34 countries
- Genetic Disorders of Mucociliary Clearance in Nontuberculous Mycobacterial Lung DiseaseCompletedNCT003684461 country
- Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex DiseaseCompletedNCT03672630Phase 2/32 countries
- Treatment of Mycobacterium Xenopi Pulmonary InfectionCompletedNCT01298336Phase 31 country
- ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation SuspensionTerminatedNCT06418711Phase 35 countries
- Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)CompletedNCT03896685Phase 36 countries
- Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB TreatmentCompletedNCT04874948Phase 11 country
- Validating the Use of Blood Transcriptomic Signatures for the Diagnosis of Active Pulmonary TuberculosisCompletedNCT049954061 country
- PredictEndTB Signature for Individualizing Treatment in Multidrug-Resistant TuberculosisTerminatedNCT04783727Not applicable4 countries
- Effect of Filarial Infection on Immune Responses in Latent TuberculosisCompletedNCT015478842 countries
- A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB)CompletedNCT01859923Phase 22 countries
- Efficacy of a Self-test and Self-alert Mobile Applet in Detecting Susceptible Infection of COVID-19CompletedNCT042563951 country
- Phase II Clinical Trial of Safety and Immunogenicity of Recombinant Subunit Tuberculosis Vaccine GamTBvacCompletedNCT03878004Phase 21 country
- Liposomal Amikacin for Inhalation (LAI) in the Treatment of Mycobacterium Abscessus Lung DiseaseCompletedNCT03038178Phase 21 country
- Study to Evaluate the Tolerability and Immunogenicity of Nyaditum Resae ® Probiotic Administered to Pediatric Population in Contact With Tuberculosis With or Without Latent Tuberculosis InfectionCompletedNCT02581579Not applicable1 country
- Immune Reconstitution Syndrome in HIV-Infected Patients Taking Antiretroviral TherapyCompletedNCT002867672 countries
- A Single Ascending Dose Study of BTZ043CompletedNCT03590600Phase 11 country
- Safety and Immunogenicity of Nyaditum Resae® Probiotic to Protect From TuberculosisCompletedNCT02076139Not applicable1 country
- Multiplex Microarray Chip-Based Diagnosis of Respiratory InfectionsTerminatedNCT012120421 country
- Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant TuberculosisCompletedNCT01856634Phase 12 countries
- Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder CancerTerminatedNCT01200992Phase 36 countries
- Immune Responses to Mycobacterium Tuberculosis (Mtb) in People With Latent Tuberculosis Infection With or Without Concomitant Helminth InfectionTerminatedNCT022251581 country
- Trial of Antimycobacterial Therapy in SarcoidosisCompletedNCT01074554Phase 1/21 country
- Etiologies, Investigations and Outcomes of Patients Presenting With HemoptysisStatus unknownNCT029133651 country
- Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder CancerCompletedNCT00406068Phase 2/32 countries
- EBUS-TBNA Versus EBUS-TBNBWithdrawnNCT01467635Not applicable2 countries
- Phase II Study of Amithiozone (Thiacetazone) for Patients With Mycobacterium Avium Complex Pulmonary DiseaseCompletedNCT00004689Phase 2
- Pilot Randomized Study of Paromomycin (Aminosidine) vs Streptomycin for Uncomplicated Pulmonary TuberculosisCompletedNCT00004444Not applicable
- The Incidence of Nontuberculous Mycobacterial Pulmonary Infection in Bilateral Bronchiectasis and BronchiolitisStatus unknownNCT013549121 country
- Rapid Identification of Mycobacteria in Acid-fast Bacilli Smear-positive Respiratory SpecimensTerminatedNCT009990761 country
- Investigation of the Efficacy of Antibiotics on Pulmonary SarcoidosisCompletedNCT01169038Phase 11 country
- Safety and Efficacy of Oral Immunomodulator in Tuberculosis (TB) and TB/HIV PatientsCompletedNCT01222338Phase 21 country
- Isoniazid Plus Antiretroviral Therapy to Prevent Tuberculosis in HIV-infected PersonsCompletedNCT00463086Not applicable1 country
- Autoantibodies Against Specific Cytokines in Adults With Severe Mycobacterial InfectionStatus unknownNCT016287441 country